Somatotropin
- Generic Name
- Somatotropin
- Brand Names
- Genotropin, Humatrope, Norditropin, Norditropin Nordiflex, Nutropin, Nutropinaq, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive, NutropinAq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 12629-01-5
- Unique Ingredient Identifier
- NQX9KB6PCL
- Background
Human growth hormone (HGH), also known as somatotropin, is a peptide hormone that is synthesized and secreted by the somatotropic cells of the anterior pituitary gland. Growth hormone plays an essential role in growth regulation during childhood as well as other basal metabolic functions, muscle and fat mass regulation, blood glucose level regulation, and li...
- Indication
Somatotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, short stature associated with Turner syndrome, Prader-Willi syndrome (PWS), idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and shor...
- Associated Conditions
- Adult Onset Growth Hormone Deficiency, Cachexia, Childhood-onset Growth Hormone Deficiency, Growth Failure, HIV Wasting Syndrome, Short Bowel Syndrome (SBS), Short Stature
- Associated Therapies
- -
Growth Response in Girls With Turner Syndrome
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 31
- Registration Number
- NCT01734486
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, Vandoeuvre Les Nancy, France
Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation
- Conditions
- Interventions
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 57
- Registration Number
- NCT01734447
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, Paris, France
Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- Ferring Pharmaceuticals
- Registration Number
- NCT01731028
Study of Growth Hormone and Bone in Obesity
- First Posted Date
- 2012-11-09
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 77
- Registration Number
- NCT01724489
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency
- Conditions
- Interventions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 7
- Registration Number
- NCT01698944
- Locations
- 🇬🇷
Novo Nordisk Investigational Site, Athens, Greece
Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 75
- Registration Number
- NCT01697644
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Rotterdam, Netherlands
Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Columbia University
- Registration Number
- NCT01647412
- Locations
- 🇺🇸
Columbia University Department of Clinical Genetics, New York, New York, United States
Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome
- Conditions
- Interventions
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2016
- Registration Number
- NCT01604161
Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
- Conditions
- Interventions
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01592500
- Locations
- 🇸🇰
Children's University Hospital, Kosice, Slovakia
🇬🇷Children's Hospital "P. A. Kyriakou", Athens, Greece
🇭🇺Buda Children's Hospital, Budapest, Hungary
French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin
- Conditions
- Interventions
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 331
- Registration Number
- NCT01580605
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.